Wednesday, February 13, 2013


This study reported in the American Journal of Ophthalmology tested .02% Tacrolimus ointment 1-3 times per day on patients with various ocular inflammatory disease.   Their results and conclusion were:

In all 3 groups, tacrolimus showed an immunosuppressive effect, especially on scleritis and Mooren ulcer. These effects included suppression of corneoscleral melting and reduction of hyperemia. In chronic cicatrizing conjunctivitis, simultaneous topical tacrolimus while tapering steroid therapy suppressed inflammatory relapse. The elevated IOP in steroid responders recovered to normal range after successful tapering of steroid. No adverse side effects were noted after 1.5 to 31 months of continuous tacrolimus treatment.
The use of topical tacrolimus ointment is effective in controlling refractory inflammatory ocular surface disease, and can reduce the need for steroid use while reducing inflammation recurrence.

Tacrolimus is currently used in the U.S. as an oral medication for the prevention of organ rejection and topically as .03%  or .1% ointment under the name Protopic for the treatment of atopic dermatologic disorders.

1 comment:

  1. Hi there! great stuff here, I'm glad that I drop by your page and found this very interesting. Thanks for posting about ocular inflammatory research. Hoping to read something like this in the future! Keep it up!
    Participating in a research study requires significant commitment on the participant’s behalf. Study visits may be lengthier, involve further testing not routinely prescribed, and require special concessions. For this, commercially-sponsored studies often offer compensation for time and trouble. Please consider this prior to evaluating whether or not you feel you or a loved one would be a viable candidate.


Leave a Comment or Question: